IDO is a key regulator of Treg/Th17 immunity [29,30], and is a known mechanism of immune suppression by tumor-associated ascites CD14+ myeloid cells from ovarian cancer patients [6]. The gene discussed is CD14; the disease is ovarian carcinoma.